Patient demographics and characteristics at baseline for Japanese patients (n = 145) with RA. Values are mean (SD) unless otherwise specified.
| Characteristics | Placebo, n = 49 | Baricitinib QD | |||
|---|---|---|---|---|---|
| 1 mg, n = 24 | 2 mg, n = 24 | 4 mg, n = 24 | 8 mg, n = 24 | ||
| Age, yrs | 51.1 (12.0) | 52.7 (12.8) | 56.1 (11.5) | 57.5 (10.4) | 53.6 (11.3) |
| Female, % (n) | 80 (39) | 92 (22) | 88 (21) | 79 (19) | 71 (17) |
| Duration of RA, yrs | 5.06 (3.96) | 6.22 (3.27) | 6.32 (4.18) | 5.86 (3.95) | 5.55 (4.62) |
| Anti-CCP–positive, % (n) | 76 (37) | 79 (19) | 83 (20) | 92 (22) | 79 (19) |
| RF-positive, % (n) | 86 (42) | 75 (18) | 79 (19) | 83 (20) | 79 (19) |
| TJC68 | 14.4 (8.9) | 10.2 (3.8) | 12.5 (7.6) | 15.5 (8.7) | 12.6 (5.5) |
| SJC66 | 10.0 (4.8) | 8.6 (2.8) | 10.5 (4.8) | 11.1 (4.8) | 11.0 (4.0) |
| Patient’s assessment of arthritis pain score* | 41.4 (28.3) | 46.6 (26.2) | 52.2 (24.8) | 54.3 (21.2) | 41.8 (20.9) |
| Patient’s global assessment of DAS* | 42.6 (24.6) | 49.2 (29.4) | 52.2 (24.8) | 49.5 (23.2) | 37.7 (23.7) |
| Physician’s global assessment of DAS* | 51.0 (17.8) | 48.2 (16.3) | 55.3 (16.9) | 56.6 (17.3) | 50.2 (14.2) |
| DAS28-CRP** | 4.72 (1.00) | 4.60 (0.77) | 4.94 (0.83) | 4.96 (0.80) | 4.67 (0.71) |
| DAS28-ESR** | 5.53 (0.98) | 5.51 (0.75) | 5.78 (0.82) | 5.77 (0.68) | 5.47 (0.74) |
| SDAI*** | 27.85 (10.52) | 25.10 (7.86) | 29.23 (9.83) | 30.81 (9.72) | 27.58 (7.81) |
| HAQ-DI† | 0.855 (0.598) | 1.005 (0.616) | 0.948 (0.663) | 0.974 (0.420) | 0.630 (0.486) |
| hsCRP level, mg/l | 12.391 (14.324) | 8.779 (7.443) | 11.009 (6.349) | 11.416 (11.978) | 12.512 (12.912) |
| ESR, mm/h | 41.0 (22.6) | 44.5 (20.8) | 46.8 (21.0) | 38.8 (17.5) | 44.0 (27.5) |
| MTX dose, mg/week | 8.8 (2.4) | 8.8 (2.6) | 8.8 (2.6) | 8.4 (1.7) | 8.8 (1.9) |
| Current use of oral corticosteroid, % (n) | 59 (29) | 50 (12) | 54 (13) | 75 (18) | 54 (13) |
| Dose of corticosteroid, mg/week‡ | 22.9 (9.96) | 26.8 (16.51) | 38.0 (19.00) | 33.6 (19.47) | 34.7 (21.83) |
↵* Range of scale 0 to 100.
↵** Range of scale 0 to 9.4.
↵*** Range of scale 0 to 86.
↵† Range of scale 0 to 3.
↵‡ Prednisolone-equivalent dose. RA: rheumatoid arthritis; QD: once daily; anti-CCP: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor; TJC68: tender joint count at 68 joints; SJC66: swollen joint count at 66 joints; DAS28: Disease Activity Score at 28 joints; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SDAI: Simplified Disease Activity Index; HAQ-DI: Health Assessment Questionnaire–Disability Index; hsCRP: high-sensitivity CRP; MTX: methotrexate.